Concurrent Investment Advisors LLC Grows Position in Merck & Co., Inc. $MRK

Key Points

• Concurrent Investment Advisors boosted its stake in Merck (MRK) by 147.1% in Q4 to 233,480 shares (about $24.58 million), and several other large funds also increased holdings, leaving institutional investors with 76.07% ownership.
• Mixed company outlook: Merck has new positives — a Google Cloud AI partnership, FDA Priority Review for KEYTRUDA regimens, and an HIV drug approval — but faces headwinds from weaker Gardasil sales and analyst expectations for a Q1 earnings decline; the consensus rating is a Moderate Buy with a $128.47 price target.

Concurrent Investment Advisors LLC grew its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 147.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 233,480 shares of the company's stock after purchasing an additional 138,990 shares during the period. Concurrent Investment Advisors LLC's holdings in Merck & Co., Inc. were worth $24,576,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. DLD Asset Management LP lifted its position in shares of Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock valued at $3,986,675,000 after buying an additional 11,000,000 shares in the last quarter. Invesco Ltd. lifted its position in shares of Merck & Co., Inc. by 16.6% during the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock valued at $1,665,585,000 after buying an additional 2,821,766 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Merck & Co., Inc. by 20.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock valued at $1,336,877,000 after buying an additional 2,735,459 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Merck & Co., Inc. by 61.6% during the 3rd quarter. Van ECK Associates Corp now owns 5,325,033 shares of the company's stock valued at $446,930,000 after buying an additional 2,029,342 shares in the last quarter. Finally, Danske Bank A S purchased a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at approximately $159,973,000. Hedge funds and other institutional investors own 76.07% of the company's stock.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 37,685 shares of the firm's stock in a transaction on Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares in the company, valued at approximately $19,368,240.08. This trade represents a 19.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the firm's stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the sale, the chief marketing officer directly owned 80,615 shares of the company's stock, valued at $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 in the last ninety days. Company insiders own 0.13% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MRK. Zacks Research upgraded Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. JPMorgan Chase & Co. increased their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a research report on Monday, April 6th. Wells Fargo & Company increased their target price on Merck & Co., Inc. from $135.00 to $150.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a research report on Friday, February 13th. Finally, Wall Street Zen upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $128.47.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced a multi‑year, enterprise‑wide partnership with Google Cloud to deploy Gemini AI and advanced cloud infrastructure for drug discovery, manufacturing and operations — a strategic move that could improve R&D productivity and long‑term margins. Read More. Read More.
• Positive Sentiment: Merck won FDA Priority Review for KEYTRUDA regimens in muscle‑invasive bladder cancer — a potential near‑term upsid e for oncology revenue if approved, supporting key growth drivers beyond vaccines. Read More.
• Positive Sentiment: Regulatory approval momentum: the company secured FDA approval for Idvynso (doravirine + islatravir) for HIV‑1 treatment, and is cited among defensive/counter‑cyclical stock picks — positives for investor sentiment and diversification of approved products. Read More.
• Neutral Sentiment: Progress on M&A: the Hart‑Scott‑Rodino waiting period expired for Merck’s tender offer to acquire Terns Pharmaceuticals, clearing an antitrust procedural hurdle and bringing the acquisition closer to closing — strategic but not immediately earnings‑material. Read More.
• Negative Sentiment: Vaccines headwinds: reports highlight a sharp slump in Gardasil sales in China and Japan, which pressures MRK’s vaccines revenue into the upcoming Q1 results and raises downside risk to top‑line guidance if the trend persists. Read More. Read More.
• Negative Sentiment: Analyst expectations: several analyst notes expect a decline in Q1 earnings and flag that Merck may lack the near‑term drivers for an earnings beat — this raises the risk of downside surprise and explains short‑term selling pressure. Read More. Read More.

Merck & Co., Inc. Trading Down 2.4%

Shares of MRK stock opened at $111.83 on Friday. The stock's fifty day moving average is $118.61 and its two-hundred day moving average is $106.74. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The firm has a market capitalization of $276.21 billion, a P/E ratio of 15.36, a PEG ratio of 2.31 and a beta of 0.26. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm's revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts expect that Merck & Co., Inc. will post 4.92 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were issued a $0.85 dividend. The ex-dividend date was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 3.0%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.